RxDoctor Payments Data

Lauren Wiebe, MD

Hospice and Palliative Medicine · Evanston, ILNPI 1811193592

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $4,775 of the $5,724 with a category attached, or 83.4%. AbbVie accounts for 66.7% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $5,160 and has fallen 97.4% since, to $136 in 2025. Among hospice and palliative medicine clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,724in general payments, 2019–2025

Across 16 payments — averaging $357.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • R-pharm US LLC$1K
  • AstraZeneca$240
  • Foundation Medicine, Inc.$141
  • Incyte Corporation$136
  • Boehringer Ingelheim$21

What the payments were for

  • Consulting fees$4,77583%
  • Travel & lodging$841%
  • Food & beverage$86515%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,724 in reported general payments places this provider in the 95th percentile of 53 hospice and palliative medicine providers in Illinois.

See all hospice and palliative medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$75,184
Medicare patients
194
Services billed
880

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase39$121,048
EliquisApixaban13$7,847
Fentanyl55$5,652
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen55$2,421
Pregabalin61$1,263
Hydromorphone Hcl44$995
Mirtazapine36$863
Oxycodone Hcl20$601
Morphine Sulfate ErMorphine Sulfate32$551
Dexamethasone26$378
Methadone Hcl34$360
Duloxetine Hcl27$348
Pantoprazole Sodium24$232
Gabapentin22$225
Tramadol Hcl26$202

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon$3,818$121,04839 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 53 hospice and palliative medicine providers in Illinois.

Other hospice and palliative medicine in Evanston

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →